Welcome!

News Feed Item

DREAM and Sage Bionetworks Open Three Big Data Challenges to Impact Biomedical and Clinical Research

Working with partners at the Broad Institute, MD Anderson Cancer Center, Rice University and the Global CEO Initiative for Alzheimer’s Disease, DREAM and Sage Bionetworks today opened three computational Challenges (https://www.synapse.org/#!Challenges:DREAM), leveraging big data in cancer and Alzheimer’s Disease. These Challenges will run until mid-September and are expected to attract the participation of hundreds of scientific teams.

Started in 2006 by IBM Research’s Dr. Gustavo Stolovitzky, the Dialogue on Reverse Engineering Assessment and Methods (DREAM) project consists of a distributed community of computational biologists who have been collaborating to run open DREAM Challenges every year; these Challenges engage diverse communities of scientists to competitively solve a specific problem in biomedicine in a given time period. In the past 7 years, DREAM has run 27 successful Challenges in systems biology, published over 60 DREAM Challenge-related papers, and aggregated a “crowd” of thousands of “DREAMERs.”

In 2013, Sage Bionetworks joined with the DREAM community to co-lead a new generation of Challenges that leverage collaborative data hosting and analysis tools available on Synapse (www.synapse.org), Sage Bionetworks’ open bioinformatics compute space. Running on Synapse, the last 6 DREAM Challenges made use of engaging features such as real-time Challenge leaderboards that score participants’ predictions and immediately report the result. In the first three month season of running Challenges together, DREAM and Sage Bionetworks were delighted to see the level of participation nearly double: Synapse’s Challenge leaderboards allowed participants to submit more than 2,000 predictions for scoring and to evolve their models throughout the competition period.

States DREAM Founder Dr. Gustavo Stolovitzky, “It is really gratifying to be opening the 9th season of DREAM Challenges where we will focus on important questions in cancer and Alzheimer’s Disease. Each year I grow more convinced that with DREAM Challenges, we’ve really hit upon a powerful approach for accelerating research. The combination of hosting exciting data sets and posing impactful Challenge questions that can be objectively evaluated makes DREAM Challenges a powerful catalyst for building new communities of experts that keep working together even after a Challenge closes.”

Anyone can sign up for the three DREAM Challenges that opened today (signup is open at https://www.synapse.org/#!Challenges:DREAM) and will close in the fall. Challenge winners will be announced in early October. Key information about each of the Challenges is provided below:

  • The Alzheimer’s Disease Big Data DREAM Challenge #1 (https://www.synapse.org/#!Synapse:syn2290704):
    • Originally announced at the White House on June 20, 2013 (http://www.whitehouse.gov/blog/2013/06/20/big-data-and-personalized-medicine). Running as a delayed DREAM8.5 Challenge.
    • Data provided by Alzheimer’s Disease Neuroimaging Initiative (ADNI), Rush University Medical Center, and The AddNeuroMed Study.
    • Funders: Alzheimer’s Research UK, Bright Focus Foundation, Pfizer Inc, the Ray and Dagmar Dolby Family Fund, the Rosenberg Alzheimer’s Project, Sanofi, Takeda.
    • Sponsor: European Medicines Agency.
    • Computational resources donated by IBM.
    • Publishing partner: Nature Neuroscience.
    • Challenge Focus: Predict the best biomarkers for early AD-related cognitive decline and for the mismatch between high amyloid levels and cognitive decline.
    • Best performers will be invited to present their results at the International Biomedical Commons Congress, to be held in Paris in April 2015.
  • The Broad-DREAM Gene Essentiality Prediction Challenge (https://www.synapse.org/Portal.html#!Synapse:syn2384331/wiki/):
    • Data provided by the Broad Institute.
    • Data Funding: NCI Cancer Target Discovery and Development (CTD2), Instituto Carlos Slim de la Salud (ICSS), EMD Serono, NCI Integrative Cancer Biology Program (ICBP), Eli Lilly and Company, Novartis and Pfizer.
    • Challenge Funding: NCI CTD2, ICBP and Washington State Life Sciences Discovery Fund (LSDF).
    • Computational resources donated by IBM.
    • Challenge Focus: Develop predictive models that can infer levels of gene dependencies (i.e. how essential each gene is to a cancer cell’s survival when suppressed), using features of the cell lines. (see Broad Institute blog about the Challenge: www.broadinstitute.org/node/5775)
    • Best performers will be invited to present their results at the DREAM track of the RECOMB/ISCB Systems and Regulatory Genomics/DREAM Conference, to be held in San Diego, California, November 10-14, 2014.
  • The DREAM9 Acute Myeloid Leukemia (AML) Outcome Prediction Challenge (https://www.synapse.org/#!Synapse:syn2455683):
    • Data provided by the MD Anderson Cancer Center.
    • Funders: NCI Integrated Cancer Biology Program (ICBP), Washington State Life Sciences Discovery Fund (LSDF) and Rice University.
    • Challenge Focus: Predict the outcome of treatment of AML patients (resistant or remission), their remission duration and overall survival based on clinical cytogenetics, known genetics markers and phosphoproteomic data.
    • Publishing partner: PLoS Computational Biology.
    • Best performers will be invited to present their results at the DREAM track of the RECOMB/ISCB Systems and Regulatory Genomics/DREAM Conference, to be held in San Diego, California, November 10-14, 2014.

The AD#1 Challenge is the first in what DREAM and Sage Bionetworks envision as a series of Grand Challenges that disrupt the “business as usual” approach to research with innovative Big Data techniques. Remarks George Vradenburg, Convener of The Global CEO Initiative on Alzheimer’s Disease, “There is high expectation internationally for the prospects of using Big Data to accelerate discovery and drug development in the Alzheimer's space. This is an exciting, first-of-its-kind global Challenge using open science techniques and big data processes to advance Alzheimer's discovery. The CEOi is pressing the edge of innovative science to accelerate Alzheimer's discovery and to achieve our national goal of preventing this disease by 2025.”

The Broad-DREAM Gene Essentiality Prediction Challenge seeks to broaden the impact of targeted cancer therapy by identifying drug targets as well as new biomarkers that can be used to identify patient populations likely to respond to a particular therapy. William Hahn, a senior associate member at the Broad Institute and an associate professor of medicine at the Dana-Farber Cancer Institute and Harvard Medical School, says, “We are excited to be a part of the DREAM competition. The next frontier of understanding cancer vulnerabilities will be shaped by predictive modeling and we look forward to the potential impact winning models will have.”

With only 25% of people diagnosed with AML surviving beyond 5 years, there is a high level of urgency to find better treatments. The DREAM9 Acute Myeloid Leukemia (AML) Outcome Prediction Challenge is designed to identify potential new drug targets as well as predictive clinical models that surpass current standards. Remarks Professor Steven Kornblau, from the Department of Leukemia at the MD Anderson Cancer Center, “It's very exciting to have my dataset selected for use in the DREAM competition. My goal has been to use proteomic information to improve patient outcomes by enabling us to match the right therapy to the right patient. I hope that the collective minds that work on this project help us to achieve this goal.”

To sign up for a Challenge and access the data sets and descriptions of the DREAM8.5 and DREAM9 Challenges, please go to: https://www.synapse.org/#!Challenges:DREAM

ABOUT THE DREAM PROJECT

The Dialogue on Reverse Engineering Assessment and Methods Project (DREAM Project), founded in 2006 by Andrea Califano (Columbia University) and Gustavo Stolovitzky (IBM), was originally conceived as an initiative to advance the nascent field of network biology through the organization of Challenges on network reconstruction and pathway inference. Since the first set of network inference challenges of 2007 (DREAM2) the concept of using collaborative-competitions as a vehicle to carry on a meaningful dialogue in the computational biology community has evolved significantly. The DREAM Challenges have brought rigor in the process of verification of computational methods, have enabled the democratization of different kinds of biological data, and have facilitated the collaboration of dozens of research teams. This success has triggered considerable interest by different government institutions and private organizations in working with DREAM to engage distributed teams to solve tough computational problems in biomedical research.

ABOUT SAGE BIONETWORKS

Sage Bionetworks is a nonprofit biomedical research organization, founded in 2009, with a vision to promote innovations in personalized medicine by enabling a community-based approach to scientific inquiries and discoveries. Sage Bionetworks strives to activate patients and to incentivize scientists, funders and researchers to work in fundamentally new ways in order to shape research, accelerate access to knowledge and transform human health. It is located on the campus of the Fred Hutchinson Cancer Research Center in Seattle, Washington and is supported through a portfolio of philanthropic donations, competitive research grants, and commercial partnerships. More information is available at www.sagebase.org.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
There is an ever-growing explosion of new devices that are connected to the Internet using “cloud” solutions. This rapid growth is creating a massive new demand for efficient access to data. And it’s not just about connecting to that data anymore. This new demand is bringing new issues and challenges and it is important for companies to scale for the coming growth. And with that scaling comes the need for greater security, gathering and data analysis, storage, connectivity and, of course, the...
Much of the value of DevOps comes from a (renewed) focus on measurement, sharing, and continuous feedback loops. In increasingly complex DevOps workflows and environments, and especially in larger, regulated, or more crystallized organizations, these core concepts become even more critical. In his session at @DevOpsSummit at 18th Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, will show how, by focusing on 'metrics that matter,' you can provide objective, transparent, and meaningfu...
Many private cloud projects were built to deliver self-service access to development and test resources. While those clouds delivered faster access to resources, they lacked visibility, control and security needed for production deployments. In their session at 18th Cloud Expo, Steve Anderson, Product Manager at BMC Software, and Rick Lefort, Principal Technical Marketing Consultant at BMC Software, will discuss how a cloud designed for production operations not only helps accelerate developer...
Artificial Intelligence has the potential to massively disrupt IoT. In his session at 18th Cloud Expo, AJ Abdallat, CEO of Beyond AI, will discuss what the five main drivers are in Artificial Intelligence that could shape the future of the Internet of Things. AJ Abdallat is CEO of Beyond AI. He has over 20 years of management experience in the fields of artificial intelligence, sensors, instruments, devices and software for telecommunications, life sciences, environmental monitoring, process...
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, will discuss how leveraging the Industrial Interne...
The IoTs will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm and share the must-have mindsets for removing complexity from the development proc...
Increasing IoT connectivity is forcing enterprises to find elegant solutions to organize and visualize all incoming data from these connected devices with re-configurable dashboard widgets to effectively allow rapid decision-making for everything from immediate actions in tactical situations to strategic analysis and reporting. In his session at 18th Cloud Expo, Shikhir Singh, Senior Developer Relations Manager at Sencha, will discuss how to create HTML5 dashboards that interact with IoT devic...
The IETF draft standard for M2M certificates is a security solution specifically designed for the demanding needs of IoT/M2M applications. In his session at @ThingsExpo, Brian Romansky, VP of Strategic Technology at TrustPoint Innovation, will explain how M2M certificates can efficiently enable confidentiality, integrity, and authenticity on highly constrained devices.
We're entering the post-smartphone era, where wearable gadgets from watches and fitness bands to glasses and health aids will power the next technological revolution. With mass adoption of wearable devices comes a new data ecosystem that must be protected. Wearables open new pathways that facilitate the tracking, sharing and storing of consumers’ personal health, location and daily activity data. Consumers have some idea of the data these devices capture, but most don’t realize how revealing and...
Struggling to keep up with increasing application demand? Learn how Platform as a Service (PaaS) can streamline application development processes and make resource management easy.
SYS-CON Events announced today that Ericsson has been named “Gold Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. Ericsson is a world leader in the rapidly changing environment of communications technology – providing equipment, software and services to enable transformation through mobility. Some 40 percent of global mobile traffic runs through networks we have supplied. More than 1 billion subscribers around the world re...
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists will dis...
We’ve worked with dozens of early adopters across numerous industries and will debunk common misperceptions, which starts with understanding that many of the connected products we’ll use over the next 5 years are already products, they’re just not yet connected. With an IoT product, time-in-market provides much more essential feedback than ever before. Innovation comes from what you do with the data that the connected product provides in order to enhance the customer experience and optimize busi...
The increasing popularity of the Internet of Things necessitates that our physical and cognitive relationship with wearable technology will change rapidly in the near future. This advent means logging has become a thing of the past. Before, it was on us to track our own data, but now that data is automatically available. What does this mean for mHealth and the "connected" body? In her session at @ThingsExpo, Lisa Calkins, CEO and co-founder of Amadeus Consulting, will discuss the impact of wea...
If there is anything we have learned by now, is that every business paves their own unique path for releasing software- every pipeline, implementation and practices are a bit different, and DevOps comes in all shapes and sizes. Software delivery practices are often comprised of set of several complementing (or even competing) methodologies – such as leveraging Agile, DevOps and even a mix of ITIL, to create the combination that’s most suitable for your organization and that maximize your busines...